Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ALK rearrange |
| Therapy | Lorlatinib |
| Indication/Tumor Type | lung adenocarcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ALK rearrange | lung adenocarcinoma | predicted - sensitive | Lorlatinib | Case Reports/Case Series | Actionable | In a clinical case study, restarting Lorbrena (lorlatinib) at 20 weeks of gestation resulted in a near complete response in the brain metastases within 1 month in a pregnant patient with metastatic lung adenocarcinoma harboring an ALK rearrangement, with normal fetal growth and delivery of a healthy baby, the patient remained in remission and the child developed normaly except a slight mental development delay at 20 months post birth (PMID: 40441332). | 40441332 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40441332) | Brief Report: Successful Pregnancy and Healthy Baby Outcome in a TKI-refractory ALK+ NSCLC Patient with CNS Metastasis Treated with Lorlatinib with Maternal-fetal Pharmacokinetics and Child Milestone Development Correlations. | Full reference... |